Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
In standard-risk acute promyelocytic leukemia, recent results have shown that all-trans retinoic acid plus arsenic trioxide combinations are at least as effective as classical all-trans retinoic acid plus anthracycline-based chemotherapy while being less myelosuppressive. However, the role of frontline arsenic trioxide is less clear in higher-risk acute promyelocytic leukemia, and access to arsenic remains limited for front-line treatment of standard-risk acute promyelocytic leukemia in many countries. In this randomized trial, we compared arsenic, all-trans retinoic acid and the "classical" c... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2018 |
Schlagwörter: | Adult / Anthracyclines/administration & dosage / Antineoplastic Combined Chemotherapy Protocols/therapeutic use / Arsenic Trioxide/administration & dosage / Belgium / Disease-Free Survival / Female / France / Humans / Leukemia / Promyelocytic / Acute/diagnosis / Acute/drug therapy / Male / Middle Aged / Switzerland / Treatment Outcome / Tretinoin/administration & dosage |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26529637 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://serval.unil.ch/notice/serval:BIB_A8F861CC78B6 |